Business Wire

MA-CAMBRIDGE-SEMANTICS

16.7.2020 14:02:15 CEST | Business Wire | Press release

Share
Merck KGaA, Darmstadt, Germany Selects Cambridge Semantics as Enterprise Data Fabric Provider

Cambridge Semantics, the leading provider of modern, graph-driven data integration for the enterprise data fabric, today announced that Merck KGaA, Darmstadt, Germany and its US-based biopharmaceutical business EMD Serono, have selected Cambridge Semantics as its data fabric provider.

Through this multi-year agreement, Cambridge Semantics will help Merck KGaA, Darmstadt, Germany establish an enterprise data fabric to support multiple data management initiatives. Cambridge Semantics’ Anzo® platform will enable Merck KGaA, Darmstadt, Germany to deliver on immediate data-driven requirements, including regulatory compliance with Identification of Medicinal Products (IDMP), while establishing a future-proof data strategy by driving further value from data and analytics.

“New regulatory requirements necessitate innovative approaches to data management,” said Jörg Werner, Associate Director Regulatory Data Governance at Merck KGaA, Darmstadt, Germany. “We selected Cambridge Semantics over other software vendors because Anzo’s underlying technology, which is based on semantics graph data models, aligns well with our data strategy to integrate and access information across research and development.”

Cambridge Semantics and Merck KGaA, Darmstadt, Germany delivered the first production solution in December 2019 focused on harmonizing and standardizing terminologies for regulatory compliance. The teams are now partnering to expand the regulatory data fabric with data from several legacy systems to provide unprecedented and comprehensive access to regularly data objects and accelerate its strategic Veeva implementation.

Cambridge Semantics’ Anzo provides a modern, graph-driven data integration platform to connect and bring meaning to all enterprise data and enable virtually anyone in an organization – from skilled data scientists to novice business users – to develop analytics-ready data sets that combine any data from any system across the enterprise. Anzo drives digital transformation and enables deep business insights when an organization’s data is highly distributed, vastly siloed, complex and when users want answers to unanticipated questions at scale and speed.

Moritz Kloft, IT Product Manager at Merck KGaA, Darmstadt, Germany added, “While we had multiple platform choices, including several based on semantics and ontology, only Cambridge Semantics has the technology, team and vision to deliver an enterprise-scale platform to support our data-driven research and development roadmap.”

“The pharmaceutical industry faces some of the most complex, critical and broad data challenges and requirements affecting business today, and it’s an industry in which having the right data can save lives,” said Chuck Pieper, Chairman and Chief Executive Officer at Cambridge Semantics. “We are incredibly proud that Merck KGaA, Darmstadt, Germany has selected Cambridge Semantics as their data management partner. We are confident that the work we do together will be transformative in building a rich data fabric and gathering new insights that Merck KGaA, Darmstadt, Germany can use for decision-making across R&D.”

Ben Szekely, Senior Vice President of Field Operations at Cambridge Semantics added, “The scale and rich history of innovation in technology R&D of Merck KGaA, Darmstadt, Germany offers the limitless potential to realize and expand our vision for the enterprise data fabric. We look forward to advancing our product roadmap and Europe-based service offerings in support of data integration and analytics initiatives of Merck KGaA, Darmstadt, Germany.”

About Cambridge Semantics

Cambridge Semantics Inc. is a modern, graph-driven data integration and analytics software company that enables seamless access to all enterprise data. Cambridge Semantics was recently recognized as a leader in Forrester Research’s Enterprise Data Fabric Wave.

The company delivers products and solutions that enable IT departments and business users across Life Sciences, Healthcare, Financial Services, Government, Manufacturing, and other industries to accelerate data delivery and to provide meaningful insights across the organization at speed and scale.

Cambridge Semantics is based in Boston, Massachusetts.

For more information visit www.cambridgesemantics.com or follow us on Facebook, LinkedIn, and Twitter: @CamSemantics.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.

The company holds the rights to the name and trademark “Merck” internationally except for the United States and Canada, where it operates in the biopharma market as EMD Serono, in life science as MilliporeSigma, and in the specialty chemicals and high/tech materials business area as EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye